Larimar Therapeutics' CTI-1601 offers hope for Friedreich's ataxia patients, with promising trial results. Check out why LRMR ...

Most people haven’t heard of the condition, but Friedreich’s ataxia is getting more attention because of a new treatment and ...

There is currently no cure for Friedreich’s ataxia. Treatment focuses on managing your symptoms and improving your quality of life to help you maintain your daily function and activities as long ...

Treatment success was measured as a change from baseline in the modified Friedreich’s Ataxia Rating Scale (mFARS) score. The mFARS is an assessment of neurological function and tests ...

A Friedreich ataxia specialist discusses how the typical clinical presentation of Friedreich's Ataxia includes early onset with symptoms such as ataxia and sensory loss, while also examining the ...

After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU.

Larimar will present three posters during the conference, one of which will also be presented as an oral presentation. The poster presentations are as follows: Effect of nomlabofusp administration on ...

"This significant milestone underscores our commitment to developing groundbreaking therapies for patients with rare, debilitating diseases such as Friedreich's ataxia. We believe this therapy has ...

Larimar Therapeutics, Inc. (NASDAQ:LRMR) is making significant strides in the development of treatments for rare diseases, particularly Friedreich's ataxia (FA). The company's lead candidate, ...

Bristol Myers Squibb is paying Prime Medicine $110 million upfront to develop reagents for ex vivo T-cell therapies. Prime, ...

Larimar Therapeutics, Inc. (NASDAQ:LRMR) is making significant strides in the development of treatments for rare diseases, particularly Friedreich's ataxia (FA). The company's lead candidate ...